ロード中...
A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
Empagliflozin (formerly known as BI 10773) is a potent, competitive, and selective inhibitor of the sodium glucose transporter SGLT2, which mediates glucose reabsorption in the early proximal tubule and most of the glucose reabsorption by the kidney, overall. Accordingly, empagliflozin treatment inc...
保存先:
| 出版年: | Naunyn Schmiedebergs Arch Pharmacol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5896322/ https://ncbi.nlm.nih.gov/pubmed/26108304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00210-015-1134-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|